SCHMITT DANIEL M 4

What Happened

• Daniel M. Schmitt, President, CEO and Director of Actuate Therapeutics, received a derivative award of 237,000 units on 2026-04-01. The filing reports the acquisition price as $0.00 (no cash paid at grant); the instrument is described as options in the filing footnote.

Key Details

• Transaction date: 2026-04-01 (report filed same day).
• Transaction type/code: Grant / Award (derivative) — code A.
• Shares/units granted: 237,000 units; reported acquisition price $0.00.
• Vesting: 25% vests on 2027-04-01; remaining 75% vests in equal monthly installments over the 36 months following that first anniversary (roughly through April 2030).
• Exercise/strike price or fair value: not disclosed in the Form 4.
• Shares owned after transaction: not reported in this filing.
• Timeliness: Filing appears timely (transaction and report dated 2026-04-01).

Context

• This was a compensation grant (derivative/options award), not an open-market purchase or sale. Such grants are common for executive compensation and vest over time; they do not represent immediate cash outlay or immediate transferable shares. The filing provides vesting terms but does not state an exercise price or immediate economic value.